Yüklüyor......
Targeted therapy for fusion-driven high-risk acute leukemia
Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend hig...
Kaydedildi:
| Yayımlandı: | Blood |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6148448/ https://ncbi.nlm.nih.gov/pubmed/30049809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-04-784157 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|